Jeffrey D Bradley
Overview
Explore the profile of Jeffrey D Bradley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
206
Citations
6819
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kei T, Luca K, Kayode O, Higgins K, Bradley J, Shelton J, et al.
Pract Radiat Oncol
. 2025 Feb;
PMID: 40015603
Purpose: This study characterizes lung SBRT dose conformity for a noncoplanar VMAT technique. Methods: Retrospectively, 288 previously treated lung SBRT cases were replanned using a VMAT technique of two ipsilateral...
2.
Fan M, Wang T, Lei Y, Patel P, Dresser S, Ghavidel B, et al.
J Appl Clin Med Phys
. 2025 Feb;
:e70010.
PMID: 39946266
Purpose: Deep learning-based segmentation of organs-at-risk (OAR) is emerging to become mainstream in clinical practice because of the superior performance over atlas and model-based autocontouring methods. While several commercial deep...
3.
Verginadis I, Citrin D, Ky B, Feigenberg S, Georgakilas A, Hill-Kayser C, et al.
Lancet
. 2025 Jan;
405(10475):338-352.
PMID: 39827884
For over a century, radiotherapy has revolutionised cancer treatment. Technological advancements aim to deliver high doses to tumours with increased precision while minimising off-target effects to organs at risk. Despite...
4.
Farris M, Mix M, Wang X, Jaszewski B, Foster N, Masters G, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2440673.
PMID: 39446327
Importance: The impact of patient-specific, disease-related, and social factors on outcomes in limited-stage small cell lung cancer (LS-SCLC) is not well defined. A post hoc secondary analysis of such factors...
5.
Kong F, Hu C, Pryma D, Duan F, Matuszak M, Xiao Y, et al.
J Clin Oncol
. 2024 Oct;
42(33):3935-3946.
PMID: 39365957
Purpose: NRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non-small cell lung cancer. NRG-RTOG1106/ECOG-ACRIN6697 (ClinicalTrials.gov identifier: NCT01507428), a randomized phase II trial, studied whether midtreatment F-fluorodeoxyglucose...
6.
Ali N, Zhou J, Eaton B, Switchenko J, Cao Y, Stokes W, et al.
J Radiosurg SBRT
. 2024 Aug;
9(2):121-128.
PMID: 39087059
Purpose: To review our initial experience with proton-based SBRT to evaluate the planning outcomes and initial patient tolerance of treatment. Patients And Methods: From Sep. 2019 to Dec. 2020, 52...
7.
Chun S, Hu C, Komaki R, Timmerman R, Schild S, Bogart J, et al.
JAMA Oncol
. 2024 Jun;
10(8):1111-1115.
PMID: 38935373
Importance: The optimal radiotherapy technique for unresectable locally advanced non-small cell lung cancer (NSCLC) is controversial, so evaluating long-term prospective outcomes of intensity-modulated radiotherapy (IMRT) is important. Objective: To compare...
8.
Gao Y, Chang C, Mandava S, Marants R, Scholey J, Goette M, et al.
Sci Rep
. 2024 Jun;
14(1):14647.
PMID: 38918458
No abstract available.
9.
Patel J, McCall N, Thomas M, Zhou J, Higgins K, Bradley J, et al.
Int J Part Ther
. 2024 Jun;
12:100016.
PMID: 38832321
Purpose: Emerging data have illuminated the impact of effective radiation dose to immune cells (EDIC) on outcomes in patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) treated with...
10.
Bakhtiar M, Butala A, Berlin E, Metz J, Bradley J, Jones J, et al.
Int J Part Ther
. 2024 May;
11:100014.
PMID: 38757084
Purpose: To identify the characteristics, indications, and toxicities among patients receiving proton beam therapy (PBT) in the final year of life at an academic medical center. Materials And Methods: A...